Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Rockefeller University
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04059588CT.gov A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Skin Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 2141-v11 (this asset) | Rockefeller University | P1 | CC · 47 |
| Prednisone | Dana-Farber Cancer Institute | P4 | BBB |
| Cyclophosphamide | Institute of Oncology Ljubljana | P2 | BB |
| Sirolimus | Dana-Farber Cancer Institute | P4 | BB |
| Nivolumab | 7 Hills Pharma, LLC | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Toray Industries, Inc | P3 | BB |
| Fludarabine | H. Lee Moffitt Cancer Center and Research Institute | P2 | BB |
| Dacarbazine | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Vinblastine | Memorial Sloan Kettering Cancer Center | P3 | BB |
+41 more in the Skin Cancer cohort
Other indications for 2141-v11
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Glioblastoma | — | P1/2 | CCC · 48 |
| Malignant Glioma | — | P1 | CC · 41 |
| Cancer | — | P1 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 2141-v11 in Skin Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/2141-v11-skin-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →